Swedencare AB (SE:SECARE)
:SECARE
Top Page
Swedencare AB
(SECARE)
Select Model
Select Model
Rating:54Neutral
Price Target:
kr28.00
▲(19.91% Upside)
Action:ReiteratedDate:02/18/26
The score is held up by solid underlying financial performance, led by strong long-term revenue expansion and positive free cash flow. It is pulled down meaningfully by weak technicals (price below all major moving averages with negative MACD) and by expensive valuation (high P/E with only a modest dividend yield).
Positive Factors
Multi-year revenue growth
Sustained revenue expansion over multiple years indicates durable demand for Swedencare’s pet-health brands and successful geographic/channel scaling. This revenue base supports steady organic growth, scale economics, and provides a platform for long-term margin recovery and product investment.
Negative Factors
Weakened profitability
Declining net income and EBIT despite revenue growth signals margin compression or higher operating costs, which erodes earnings quality and returns on capital. If persistent, weaker profitability can limit reinvestment capacity, slow deleveraging and reduce long-term shareholder returns.
Read all positive and negative factors
Positive Factors
Negative Factors
Multi-year revenue growth
Sustained revenue expansion over multiple years indicates durable demand for Swedencare’s pet-health brands and successful geographic/channel scaling. This revenue base supports steady organic growth, scale economics, and provides a platform for long-term margin recovery and product investment.
Read all positive factors
Swedencare AB (SECARE) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr4.38B
Dividend Yield0.66%
Average Volume (3M)305.00K
Price to Earnings (P/E)93.6
Beta (1Y)0.66
Revenue Growth6.65%
EPS Growth1.41%
CountrySE
Employees587
SectorConsumer Defensive
Sector Strength42
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.10
Shares Outstanding159,840,960
10 Day Avg. Volume222,741
30 Day Avg. Volume305,002
Financial Highlights & Ratios
PEG Ratio-2.54
Price to Book (P/B)0.92
Price to Sales (P/S)2.27
P/FCF Ratio22.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr55.00Price Target Upside135.55% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)1.36
Revenue Forecast (FY)kr2.88B
Swedencare AB Business Overview & Revenue Model
Company Description
Swedencare AB (publ), together with its subsidiaries, develops, manufactures, markets, and sells pet healthcare products. It offers ProDen PlaqueOff powder, a food supplement for cats and dogs, which reduce the formation of plaque and tartar; ProD...
How the Company Makes Money
Swedencare makes money primarily by selling pet health products to business customers and consumers through multiple channels. Key revenue streams include: (1) Product sales to veterinary clinics and veterinary distributors, where Swedencare suppl...
Swedencare AB Financial Statement Overview
Summary
Income Statement
68
Positive
Balance Sheet
70
Positive
Cash Flow
64
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.69B | 2.54B | 2.34B | 1.83B | 770.44M |
| Gross Profit | 1.52B | 1.46B | 1.29B | 1.02B | 385.87M |
| EBITDA | 446.00M | 549.50M | 484.00M | 392.40M | 138.73M |
| Net Income | 55.50M | 98.90M | 58.60M | 94.50M | 54.62M |
Balance Sheet | |||||
| Total Assets | 9.51B | 10.32B | 9.52B | 10.00B | 3.47B |
| Cash, Cash Equivalents and Short-Term Investments | 103.00M | 186.80M | 237.30M | 245.07M | 136.09M |
| Total Debt | 2.10B | 1.51B | 1.66B | 1.91B | 721.53M |
| Total Liabilities | 2.84B | 2.28B | 2.32B | 2.54B | 1.05B |
| Stockholders Equity | 6.66B | 8.03B | 7.21B | 7.46B | 2.42B |
Cash Flow | |||||
| Free Cash Flow | 275.60M | 287.80M | 408.00M | 185.51M | 98.06M |
| Operating Cash Flow | 326.80M | 359.10M | 444.00M | 260.20M | 125.85M |
| Investing Cash Flow | -531.40M | -151.90M | -176.40M | -4.67B | -1.87B |
| Financing Cash Flow | 137.80M | -274.20M | -271.60M | 4.49B | 1.59B |
Swedencare AB Technical Analysis
Neutral
23.35
Price Trends
24.53
Positive
30.46
Negative
34.56
Negative
Market Momentum
0.31
Negative
67.39
Neutral
86.00
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SECARE, the sentiment is Neutral. The current price of 23.35 is below the 20-day moving average (MA) of 24.60, below the 50-day MA of 24.53, and below the 200-day MA of 34.56, indicating a neutral trend. The MACD of 0.31 indicates Negative momentum. The RSI at 67.39 is Neutral, neither overbought nor oversold. The STOCH value of 86.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:SECARE.
Swedencare AB Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | kr12.14B | 32.29 | 24.35% | 1.95% | 7.88% | -6.35% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
56 Neutral | kr641.88M | -60.92 | -48.65% | ― | -60.33% | 58.04% | |
56 Neutral | kr730.63M | -8.89 | ― | ― | 19.17% | 24.53% | |
54 Neutral | kr4.38B | 93.57 | 0.88% | 0.66% | 6.65% | 1.41% | |
47 Neutral | kr731.61M | -8.03 | ― | ― | -8.79% | -91.09% | |
41 Neutral | kr30.21M | -1.77 | ― | ― | ― | ― |
* Consumer Defensive Sector Average
SE:SECARE
Swedencare AB
27.40
-8.38
-23.43%
SE:BIOG.B
BioGaia AB
120.00
25.30
26.72%
SE:ORX
Orexo AB
20.95
6.59
45.89%
SE:NANEXA
Nanexa AB
3.90
2.60
200.46%
SE:ENZY
Enzymatica AB
3.01
-0.39
-11.47%
SE:ERMA
Enorama Pharma AB
0.41
-1.72
-80.99%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.